Fifth Third Wealth Advisors LLC acquired 1,415 shares in
PTC Inc.. Investors have considered whether the recent weakness in PTC Inc.'s stock suggests the market might be overlooking the company's strong financial prospects. The first week of March saw active options trading for PTC. Analysts suggest that the price action of PTC stock could be used advantageously.
Assenagon Asset Management S.A. purchased 46,017 shares of PTC Inc., but also reported a decrease in PTC Therapeutics shares. A Q4 earnings preview for PTC has been released. PTC's stock rose significantly, particularly in relation to the rest of the market, after a substantial licensing agreement was struck with Novartis, and after it was identified as a solid long-term investment. Oak Thistle LLC made a new investment in PTC Inc., and PTC's stake was further increased by
JPMorgan Chase & Co.. The projected price target for PTC Inc. is at $207.54.
Novartis' $2.9 Billion Huntington's bet saw PTC's stock surge, and their status was even further boosted by exceeding Q4 earnings estimates. Shares in PTC have risen by 145% over the last five years. However, investors should note several insider sales of PTC Therapeutics shares.
PTC Stocks News Analytics from Mon, 20 May 2024 07:00:00 GMT to Sat, 18 Jan 2025 09:05:21 GMT -
Rating 6
- Innovation 8
- Information 7
- Rumor -9
